Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Shionogi & Co., Ltd.
Shionogi makes and sells prescription medicines, over-the-counter drugs, diagnostic tests, and medical devices for patients and healthcare providers.
Shionogi is a Japanese drugmaker that sells medicines to patients and the doctors and hospitals that treat them. Its core business is prescription drugs, but it also sells over-the-counter remedies, diagnostic reagents, and medical devices. The company is headquartered in Osaka, and it has been in the medicine business for a very long time.
The heart of the business is discovering and selling prescription medicines. A drug company spends years and huge sums testing whether a molecule actually helps sick people, then it asks regulators for permission to sell it. Once approved, the medicine can earn money for years. Shionogi is known for infectious disease treatments and for pain and central nervous system drugs, and it has pushed into new areas as well. The most interesting thing about Shionogi right now is a bet most people would not expect from a mid-sized Japanese drugmaker: a pill to treat COVID-19. The company developed ensitrelvir, sold in Japan as Xocova, an antiviral taken by mouth rather than through a needle. That matters because pills are far easier to hand out than infusions, and the company has been seeking approval and partners to sell it more widely, including work with Pfizer on global commercialization. It is a reminder that Shionogi competes on science, not on size — the big players like Pfizer and Merck are far larger.
Shionogi also owns a stake in a healthcare data business, which fits its broader push into diagnostics and digital health. The stock is a steady, dividend-paying kind of holding rather than a rocket ship. The risks are the usual ones for drugmakers: a clinical trial can fail, a patent can expire and invite cheap copycat pills, and government price cuts can squeeze margins. When it works, though, one good drug can pay for a lot of failed experiments.
Saved answer · last researched 12 Nov 2026